Construction of a new workshop for production of medicines
Enterprise and its description
Ekzon, JSC
Year of establishment2010
Primary activityproduction of pharmaceutical preparations
Superior bodyThe Pharmaceutical Holdings Company "Belpharmprom"
General reference and analytical information about the companyEkzon is a modern pharmaceutical company that produces more than a hundred names of medicines and biologically active food additives.
Authorized capital size of the company, thousand $314
Distribution of shares (by owners)state owned - 99,1964 %, private (individuals) - 0,8036 %
Net profit (net loss), thousand $1 285
Current liquidity ratio3.06
Number of employees as on the month of filling the form, people270
Average salary as on the month of filling the form, BYN1 189,5
Project description
Project in progress
Total volume of investments, thousand $25800
Expected input of an investor, thousand $20000
Project period2021-2027
Investor participation formnew enterprise
Project descriptionThe project is aimed at ensuring the efficient operation of the enterprise, creating a production of ready-made medicines that meets the license conditions, the requirements of TCP030-2017 "Good Manufacturing Practice" (GMP), as well as ISO 22000:2005 "Food safety management System. Requirements for all organizations in the food production and consumption chain".
The nomenclature of the product to be produced with indication of the CN FEA codeTablets (3004900002, 3004500006, 3004900009, 3004320009, 3004490009); Powders (2932190000, 3004900002, 3004900009, 2936270000, 1702305000); Syrups (3004900002, 2106905900); Suspensions (3004900002); Drops (2106909200, 3004490009); Sprays (3004200002, 3004320009); Suppositories (3004900002); Solutions (3004900009, 3004900002, 2106905900); Aerosols (3004900009, 3004500002, 3004320009); Capsules (3004490009, 3004900002).
Annual revenues once fully operational (without VAT, thousand $)2500
Simple pay-back period, yrs16.68
Dymanic pay-back period, yrs16.68
NPV, thousand $1 359,6
IRR, %6.88
Discount Rate, %6.28
Potential customerSales markets of near and far abroad: CIS countries, EAEU countries, EU countries
Key benefits of the project1) Establishment of the enterprise which comply with all the licensing requirement and the requirements of TKP 030-2017 "Good Manufacturing Practice (GMP)”. 2) Products differentation and the opportunity of export the medicines in EEU and EU countries. 3) Production of high-quality, effective and safe import-substituting medicines. Reducing the using of currency to the buying the similar medicines to import in general for country.
Level of project developmentPre-project (pre-investment) documentation is being developed
© National Agency of Investment and Privatization, 2023
We are in social networks
